Active Filter(s):
Details:
CSL Behring advances Ig clinical trial program to address need in treating serious autoimmune disease.
Lead Product(s): Human Rho D Immune Globulin
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2020